Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (121-130 of 269) with videos related to

Pageof 27
Sort By:
Journal of Crohn'S & Colitis|August 17, 2021
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised TrialSéverine Vermeire, Geert D'Haens, Filip Baert, et al.
Gastrointestinal Endoscopy|October 9, 2004
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDMarco Daperno, Geert D'Haens, Gert Van Assche, et al.
Gut|February 26, 2013
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II studySimon P L Travis, Silvio Danese, Limas Kupcinskas, et al.
Acta Gastro-Enterologica Belgica|March 7, 2003
The role of aminosalicylates in the treatment of ulcerative colitisGert Van Assche, Filip Baert, Marc De Reuck, et al.
Gut|June 22, 2014
A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's diseaseKrisztina B Gecse, Willem Bemelman, Michael A Kamm, et al.
Clinical and Translational Gastroenterology|March 7, 2023
Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 StudyBoyd Steere, Jochen Schmitz, Nick Powell, et al.
Gastro Hep Advances|August 12, 2024
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 StudiesLaurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, et al.
Crohn'S & Colitis 360|April 24, 2026
Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trialWalter Reinisch, Laurent Peyrin-Biroulet, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|August 5, 2016
Evolving Concepts in Phases I and II Drug Development for Crohn's DiseaseVipul Jairath, Barrett G Levesque, Niels Vande Casteele, et al.
Nature Communications|April 28, 2026
Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn's Disease: a first in human trialPerle Guarino-Vignon, Edouard Louis, Hang-Phuong Pham, et al.
Pageof 27

Showing results (121-130 of 269) with videos related to

Sort By:
Pageof 27
Journal of Crohn'S & Colitis|August 17, 2021
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised TrialSéverine Vermeire, Geert D'Haens, Filip Baert, et al.
Gastrointestinal Endoscopy|October 9, 2004
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDMarco Daperno, Geert D'Haens, Gert Van Assche, et al.
Gut|February 26, 2013
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II studySimon P L Travis, Silvio Danese, Limas Kupcinskas, et al.
Acta Gastro-Enterologica Belgica|March 7, 2003
The role of aminosalicylates in the treatment of ulcerative colitisGert Van Assche, Filip Baert, Marc De Reuck, et al.
Gut|June 22, 2014
A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's diseaseKrisztina B Gecse, Willem Bemelman, Michael A Kamm, et al.
Clinical and Translational Gastroenterology|March 7, 2023
Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 StudyBoyd Steere, Jochen Schmitz, Nick Powell, et al.
Gastro Hep Advances|August 12, 2024
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 StudiesLaurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, et al.
Crohn'S & Colitis 360|April 24, 2026
Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trialWalter Reinisch, Laurent Peyrin-Biroulet, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|August 5, 2016
Evolving Concepts in Phases I and II Drug Development for Crohn's DiseaseVipul Jairath, Barrett G Levesque, Niels Vande Casteele, et al.
Nature Communications|April 28, 2026
Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn's Disease: a first in human trialPerle Guarino-Vignon, Edouard Louis, Hang-Phuong Pham, et al.
Pageof 27